Arrowhead Pharmaceuticals (ARWR) Income from Non-Controlling Interests (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) reported Income from Non-Controlling Interests of $15.36 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), compared with -$3.41 million a year earlier.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Arrowhead Pharmaceuticals' Income from Non-Controlling Interests came in at $47.83 million; for FY2025 (ended Sep 30, 2025), it was $31.75 million.
- By fiscal year, Income from Non-Controlling Interests came in at -$10.2 million in FY2024, -$4 million in FY2023 and -$431,000 in FY2022.
- Five-year quarterly Income from Non-Controlling Interests spans a low of -$4.84 million in fiscal Q2 2026 and a high of $39.87 million in fiscal Q4 2025.
- Per Business Quant data, the three fiscal quarters before Q3 2026 came in at -$4.84 million (Q2 2026), -$2.57 million (Q1 2026) and $39.87 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | - |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.00 Mn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -2.00 Mn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | -7.00 Mn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 1.00 Mn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | - |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 10.00 Mn |
| 10 | Arrowhead Pharmaceuticals | 9.06 Bn | 3.84 Bn | - | 15.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.36 Mn |
| Mar 31, 2026 | -4.84 Mn |
| Dec 31, 2025 | -2.57 Mn |
| Sep 30, 2025 | 39.87 Mn |
| Jun 30, 2025 | -3.41 Mn |
| Mar 31, 2025 | -2.58 Mn |
| Dec 31, 2024 | -2.13 Mn |
| Sep 30, 2024 | -2.81 Mn |
| Jun 30, 2024 | -3.18 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Dec 31, 2023 | -2.51 Mn |
| Sep 30, 2023 | -1.34 Mn |
| Jun 30, 2023 | -1.18 Mn |
| Mar 31, 2023 | -999,000.00 |
| Dec 31, 2022 | -486,000.00 |
| Sep 30, 2022 | -431,000.00 |
| Sep 30, 2014 | -90.00 |
| Jun 30, 2014 | 2,468.00 |
| Mar 31, 2014 | -40,179.00 |
| Dec 31, 2013 | -57,420.00 |
API Access
Arrowhead Pharmaceuticals Income from Non-Controlling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=ARWR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "ARWR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=ARWR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();